Interview with Dr Marian Kelley (MKelley Consulting) on her current work, new technologies and regulatory challenges

Written by Thomas Payne, Future Science Group

Could you tell Bioanalysis Zone a little about your career to date and how you ended up in your current role? For many years I headed up a Hybridoma research group at both DuPont and Sterling Drug to support drug screening, which entailed not only fusions and monoclonal antibody screening, but also antibody scale up and conjugations, and finally method development. So I guess you could say I brought a solid foundation in method development to J&J when I joined Pharmaceutical Research and Development (PRD) in Rartian, NJ, USA. What I needed was a crash course in the GLP regulations...

To view this content, please register now for access

It's completely free